Mutagenesis studies identified an androgen receptor mutation that converts enzalutamide-a drug recently approved for the treatment of advanced prostate cancer-into an androgen receptor agonist, and modeling studies informed the design of novel drugs that are effective against the mutant receptor.

A protein called PVRL4 has a central role in a number of cancers that originate in epithelial tissue, and anti-PVRL4 antibodies could be used to treat some of these cancers.

Chronic and excessive inflammation can lead to exhaustion of the supply of hematopoietic stem cells and to myeloid malignancies in mice, mimicking important aspects of the myelodysplastic syndrome found in humans.

When a protein involved in DNA repair malfunctions, it can anneal RNA molecules to DNA molecules, creating hybrids that increase the frequency of mutations in the DNA.

Lysine-specific demethylase 1 (Lsd1) has an essential role during both the early and later stages of blood cell development.

A study that models the evolution of drug resistance in tumors reveals that drugs are more effective when given in combination than sequentially, and that cure is much more likely when the drugs target different pathways.

Nutrient limitation elicits differential responses in cells lacking the tumor suppressor PTEN and in normal cells, resulting in hyperplastic overgrowth of PTEN mutant tissue independent of additional mutations.

Reduced expression of MYBL2 contributes to malignancies of the blood by permitting uncontrolled expansion of blood cell progenitors, implying a tumor suppressor function for this gene.